Can Omada do a Livongo?
Omada is better funded than its digital health rival Livongo, but can it achieve a similar valuation?
AASLD 2020 – Nash updates from Novo and Inventiva in focus
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Will Novo’s pivotal push also include Alzheimer’s?
Novo’s late-stage pipeline is set to balloon with three new pivotal trials planned; data due in Alzheimer’s could add a whole new storyline.
Lilly swerves the worst case for its Covid-19 antibody
Bamlanivimab bucks could help Lilly bounce back from a soft third quarter, but diabetes is the big focus.
Bayer faces an uphill fight with finerenone
Pivotal data on finerenone might see it approved, but competing in the market will be trickier.
The window of opportunity opens wider for Ascendis
With the previous incumbent withdrawn from the market Ascendis hails a new hormone replacement for hypoparathyroidism.
